Vanda Pharmaceuticals, Inc. Earnings Conference Call (Q2 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Aug 10 Calls Today's Calls

Call Details Vanda Pharmaceuticals, Inc. Earnings Conference Call (Q2 2009) Mon, Aug 10, 2009, 10:00 am Eastern Listen to the archived event audio About Vanda Pharmaceuticals, Inc. (NasdaqGM:VNDA) Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of clinical-stage drug candidates for central nervous system disorders. Its product portfolio includes Iloperidone (oral), a compound for the treatment of schizophrenia completed Phase III clinical trial; and Tasimelteon, which completed Phase III clinical trials for transient insomnia and chronic primary insomnia. The company’s products also comprise Iloperidone (Injectible) for the treatment of schizophrenia and Tasimelteon for the treatment of depression, which are in the Phase II initiation status. Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings